Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.140 -0.040 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,306,178
Open 3.180
Bid (Size) 3.140 (31)
Ask (Size) 3.180 (1)
Prev. Close 3.180
Today's Range 3.100 - 3.210
52wk Range 2.190 - 18.89
Shares Outstanding 65,837,894
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 
Via Stocktwits
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga

Performance

YTD
-75.3%
-75.3%
1 Month
-3.7%
-3.7%
3 Month
+11.7%
+11.7%
6 Month
-39.5%
-39.5%
1 Year
-81.3%
-81.3%

More News

Read More
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Which stocks are experiencing notable movement on Wednesday?
Via Chartmill
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
Via Stocktwits
Topics Death
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
Via Benzinga
Wednesday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Rocket Pharma Stock Up 15% Pre-Market Today?
Via Stocktwits
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
From Faruqi & Faruqi, LLP
Via Business Wire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Via NewMediaWire
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
From Pomerantz LLP
Via GlobeNewswire
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)
Via TheNewswire.com
Topics Fraud Lawsuit
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)
Via NewMediaWire
Topics Fraud Lawsuit
Rocket (RCKT) Q2 Loss Narrows 16%
Via The Motley Fool
Topics Intellectual Property
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
From The Rosen Law Firm PA
Via GlobeNewswire
August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?
Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market
What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?
The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 3.140
When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 10/07/25 04:00 PM ET
What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 206.73M
How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?
Rocket Pharmaceuticals, Inc. - Common Stock has 207M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.